An assessment of the public health impact of lowering the routine cohort age for herpes zoster (HZ) vaccination in England
PHE ePoster Library. Jinadu G.
Sep 12, 2017; 186690
Mr. Gideon Jinadu
Mr. Gideon Jinadu
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Abstract BACKGROUND AND AIM: Herpes zoster (HZ) or “Shingles”, is a viral infection causing a painful skin rash. 68% of UK HZ cases occur in people over 50. The annual vaccination programme targets 70-year-olds. We explore the public health impact of the routine vaccination age changing to 65.METHODS:A static, multi-cohort Markov model was used, in which individuals transition through the infection stages including: no HZ, HZ, post-herpetic neuralgia (PHN), recovery, recurrent HZ. The two-dose candidate HZ adjuvanted subunit vaccine (HZ/su) is compared with: 'no vaccination' and the current vaccine, Zoster Vaccine Live (ZVL) across two age cohorts of 100,000 people, using a lifetime perspective. Using 2015/16 Public Health England data for HZ, we assume a first dose coverage of 54.9%, and a second dose compliance of 70%. RESULTS: Compared with no vaccination, HZ/su is expected to prevent:• 6,482 HZ and 936 PHN cases for 65-year-olds• 5,000 HZ and 788 PHN cases for 70-year-oldsCompared with no vaccination, ZVL is expected to prevent:• 2,577 HZ and 363 PHN cases in 65-year-olds• 1,273 HZ and 511 PHN cases in 70-year-olds To avoid one HZ case, the number needed to vaccinate is expected to be:• 8 and 11 for 65- and 70-year-olds respectively - HZ/su vs. no vaccination • 21 and 43 for 65- and 70-year-olds respectively - ZVL vs. no vaccinationCONCLUSIONS: A lower HZ vaccination age could result in UK public health benefits. Vaccinating 65-year-olds with HZ/su is likely to reduce HZ and PHN cases in the UK. External funding details GlaxoSmithKline Biologicals S.A. funded this study (GSK study identifier: HO-17-18398) and all costs related to the development of the abstract. All authors are employees of the GSK group of companies and DC, HSC and MH hold shares in the GSK group of companies.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings